Literature DB >> 25758994

The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndrome.

Michael Frank1,2, Juliette Albuisson1,2,3, Brigitte Ranque2,3,4, Lisa Golmard1,3, Jean-Michael Mazzella1, Laurence Bal-Theoleyre5, Anne-Laure Fauret1,3, Tristan Mirault1,3, Nicolas Denarié1, Elie Mousseaux3,6, Pierre Boutouyrie2,3,7, Jean-Noël Fiessinger1,3, Joseph Emmerich1,3, Emmanuel Messas1,2,3, Xavier Jeunemaitre1,2,3.   

Abstract

Vascular Ehlers-Danlos syndrome (vEDS) is a rare and severe autosomal dominant disorder caused by variants at the COL3A1 gene. Clinical characteristics and course of disease of 215 molecularly proven patients (146 index cases and 69 relatives) were analysed. We found 126 distincts variants that were divided into five groups: (1) Glycine substitutions (n=71), (2) splice-site and in-frame insertions-deletions (n=36), (3) variants leading to haplo-insufficiency (n=7), (4) non-glycine missense variants within the triple helix (n=4 variants), and (5) non-glycine missense variants or in-frame insertions-deletions, in the N- or C-terminal part of the protein (n=8). Overall, our cohort confirmed the severity of the disease with a median age at first complication of 29 years (IQR 22-39), the most frequent being arterial (48%) and digestive (24%) ruptures. Groups 2 and 1 were significantly more severe than groups 3-5, with extreme median ages at first major complication of 23-47 years. Patients of groups 3-5 had a less typical phenotype and remarkably absence of digestive events. The distribution of glycine-replacing amino acids was strongly biased towards more destabilizing residues of the collagen assembly. Thus the natural course of vEDS and the clinical phenotype of patients are influenced by the type of COL3A1 variant. This study also confirms that patients with variants located in the C- and N-termini or leading to haplo-insufficiency have milder course of the disease and less prevalent diagnostic criteria. These findings may help refine diagnostic strategy, genetic counselling and clinical care.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25758994      PMCID: PMC4795191          DOI: 10.1038/ejhg.2015.32

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  19 in total

1.  Revised diagnostic criteria for the Marfan syndrome.

Authors:  A De Paepe; R B Devereux; H C Dietz; R C Hennekam; R E Pyeritz
Journal:  Am J Med Genet       Date:  1996-04-24

2.  The Human Collagen Mutation Database 1998.

Authors:  R Dalgleish
Journal:  Nucleic Acids Res       Date:  1998-01-01       Impact factor: 16.971

3.  COL3A1 mutations cause variable clinical phenotypes including acrogeria and vascular rupture.

Authors:  F M Pope; P Narcisi; A C Nicholls; D Germaine; G Pals; A J Richards
Journal:  Br J Dermatol       Date:  1996-08       Impact factor: 9.302

Review 4.  Heritable diseases of collagen.

Authors:  D J Prockop; K I Kivirikko
Journal:  N Engl J Med       Date:  1984-08-09       Impact factor: 91.245

5.  Haploinsufficiency for one COL3A1 allele of type III procollagen results in a phenotype similar to the vascular form of Ehlers-Danlos syndrome, Ehlers-Danlos syndrome type IV.

Authors:  U Schwarze; W I Schievink; E Petty; M R Jaff; D Babovic-Vuksanovic; K J Cherry; M Pepin; P H Byers
Journal:  Am J Hum Genet       Date:  2001-09-27       Impact factor: 11.025

6.  Characterization of 11 new mutations in COL3A1 of individuals with Ehlers-Danlos syndrome type IV: preliminary comparison of RNase cleavage, EMC and DHPLC assays.

Authors:  C Giunta; B Steinmann
Journal:  Hum Mutat       Date:  2000-08       Impact factor: 4.878

7.  COL3A1 haploinsufficiency results in a variety of Ehlers-Danlos syndrome type IV with delayed onset of complications and longer life expectancy.

Authors:  Dru F Leistritz; Melanie G Pepin; Ulrike Schwarze; Peter H Byers
Journal:  Genet Med       Date:  2011-08       Impact factor: 8.822

8.  Stability related bias in residues replacing glycines within the collagen triple helix (Gly-Xaa-Yaa) in inherited connective tissue disorders.

Authors:  Anton V Persikov; Rian J Pillitteri; Priyal Amin; Ulrike Schwarze; Peter H Byers; Barbara Brodsky
Journal:  Hum Mutat       Date:  2004-10       Impact factor: 4.878

9.  Vascular Ehlers-Danlos syndrome mutations in type III collagen differently stall the triple helical folding.

Authors:  Kazunori Mizuno; Sergei Boudko; Jürgen Engel; Hans Peter Bächinger
Journal:  J Biol Chem       Date:  2013-05-03       Impact factor: 5.157

10.  Survival is affected by mutation type and molecular mechanism in vascular Ehlers-Danlos syndrome (EDS type IV).

Authors:  Melanie G Pepin; Ulrike Schwarze; Kenneth M Rice; Mingdong Liu; Dru Leistritz; Peter H Byers
Journal:  Genet Med       Date:  2014-06-12       Impact factor: 8.822

View more
  50 in total

1.  A multi-institutional experience in vascular Ehlers-Danlos syndrome diagnosis.

Authors:  Sherene Shalhub; Peter H Byers; Kelli L Hicks; Dawn M Coleman; Frank M Davis; Giovanni De Caridi; K Nicole Weaver; Erin M Miller; Marc L Schermerhorn; Katie Shean; Gustavo Oderich; Mauricio Ribeiro; Cole Nishikawa; Kristofer Charlton-Ouw; Christian-Alexander Behrendt; E Sebastian Debus; Yskert von Kodolitsch; Devin Zarkowsky; Richard J Powell; Melanie Pepin; Dianna M Milewicz; Ellen S Regalado; Peter F Lawrence; Karen Woo
Journal:  J Vasc Surg       Date:  2019-07-26       Impact factor: 4.268

2.  Arterial fragility in kyphoscoliotic Ehlers-Danlos syndrome.

Authors:  Pierrick Henneton; Anne Legrand; Cecilia Giunta; Michael Frank
Journal:  BMJ Case Rep       Date:  2018-07-06

3.  A multi-institutional experience in the aortic and arterial pathology in individuals with genetically confirmed vascular Ehlers-Danlos syndrome.

Authors:  Sherene Shalhub; Peter H Byers; Kelli L Hicks; Kristofer Charlton-Ouw; Devin Zarkowsky; Dawn M Coleman; Frank M Davis; Ellen S Regalado; Giovanni De Caridi; K Nicole Weaver; Erin M Miller; Marc L Schermerhorn; Katie Shean; Gustavo Oderich; Mauricio Ribeiro; Cole Nishikawa; Christian-Alexander Behrendt; E Sebastian Debus; Yskert von Kodolitsch; Richard J Powell; Melanie Pepin; Dianna M Milewicz; Peter F Lawrence; Karen Woo
Journal:  J Vasc Surg       Date:  2019-05-21       Impact factor: 4.268

Review 4.  The Ehlers-Danlos syndromes.

Authors:  Fransiska Malfait; Marco Castori; Clair A Francomano; Cecilia Giunta; Tomoki Kosho; Peter H Byers
Journal:  Nat Rev Dis Primers       Date:  2020-07-30       Impact factor: 52.329

Review 5.  Vascular Genetics: Presentations, Testing, and Prognostics.

Authors:  Aaron W Aday; Sarah E Kreykes; Christina L Fanola
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-11-13

Review 6.  Genotype-phenotype correlations in pathology caused by collagen type IV alpha 1 and 2 mutations.

Authors:  Marion Jeanne; Douglas B Gould
Journal:  Matrix Biol       Date:  2016-10-26       Impact factor: 11.583

Review 7.  Type III collagen (COL3A1): Gene and protein structure, tissue distribution, and associated diseases.

Authors:  Helena Kuivaniemi; Gerard Tromp
Journal:  Gene       Date:  2019-05-07       Impact factor: 3.688

Review 8.  Genes Associated with Thoracic Aortic Aneurysm and Dissection: An Update and Clinical Implications.

Authors:  Adam J Brownstein; Bulat A Ziganshin; Helena Kuivaniemi; Simon C Body; Allen E Bale; John A Elefteriades
Journal:  Aorta (Stamford)       Date:  2017-02-01

9.  Efficient C•G-to-G•C base editors developed using CRISPRi screens, target-library analysis, and machine learning.

Authors:  Luke W Koblan; Mandana Arbab; Max W Shen; Jeffrey A Hussmann; Andrew V Anzalone; Jordan L Doman; Gregory A Newby; Dian Yang; Beverly Mok; Joseph M Replogle; Albert Xu; Tyler A Sisley; Jonathan S Weissman; Britt Adamson; David R Liu
Journal:  Nat Biotechnol       Date:  2021-06-28       Impact factor: 54.908

Review 10.  Hypermobile Ehlers-Danlos syndromes: Complex phenotypes, challenging diagnoses, and poorly understood causes.

Authors:  Cortney Gensemer; Randall Burks; Steven Kautz; Daniel P Judge; Mark Lavallee; Russell A Norris
Journal:  Dev Dyn       Date:  2020-08-17       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.